Bolt Biotherapeutics Inc reports results for the quarter ended in June - Earnings Summary

Bolt Biotherapeutics

10/08/2022 21:48

* Bolt Biotherapeutics Inc  BOLT.OQ  reported a quarterly
adjusted
loss of 61 cents​​ per share for the quarter ended in June. The
mean expectation of four analysts for the quarter was for a loss
of 68 cents per share.
    * Revenue was $1.39 million​; analysts expected $375.00
thousand. 
    * Bolt Biotherapeutics Inc's reported EPS for the quarter
was a
loss of 61 cents​.
    * The mean earnings estimate of analysts had risen by
about 7.2%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Bolt Biotherapeutics Inc shares had risen by 11.8% this
quarter and lost 53.5% so far this year.
    * The company reported a quarterly loss of $22.66 million.
    * Wall Street's median 12-month price target for Bolt
Biotherapeutics Inc is $8.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 10
at 08:48 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.68          -0.61          Beat
 Mar. 31 2022      -0.72          -0.64          Beat
 Dec. 31 2021      -0.82          -0.73          Beat
 Sep. 30 2021      -0.65          -0.63          Beat